Table 1.

Plasma Human Immunodeficiency Virus Type 1 RNA Levels at Week 16 of the Analytic Treatment Interruption

HLA group	Pa	Treatment arm, median		Pb
		Vaccine	Placebo
Protective	.01	4.6 (n = 32)	4.4 (n = 6)
Neutral		4.0 (n = 36)	4.5 (n = 27)	.02
Unfavorable		5.7 (n = 5)	N/A (n = 4)

NOTE. Data are median log₁₀ plasma HIV-1 RNA copies/mL, with the number of participants contributing to the analysis shown in parentheses. The median is calculated on the basis of the assumption that the missing values are greater than the greatest observed value. When the number of missing values is more than half the sample size, the median is reported as “N/A”. Three of the 4 participants in the placebo group with unfavorable HLA alleles did not complete the week 16 evaluation, including 2 participants who met protocol-defined criteria for reinitiation of ART prior to ATI week 16. NA, not applicable.

^aComparison of the vaccine/protective and vaccine/neutral subgroups.

^bComparison of the vaccine/neutral and placebo/neutral subgroups.